Exelixis Inc. Stock
Exelixis Inc. Stock
Exelixis Inc. shows a slight decrease today, losing -€0.135 (-0.360%) compared to yesterday.
The stock is one of the favorites of our community with 30 Buy predictions and 1 Sell predictions.
As a result the target price of 42 € shows a slightly positive potential of 11.48% compared to the current price of 37.68 € for Exelixis Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Exelixis Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Exelixis Inc. in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Exelixis Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Exelixis Inc. | -0.360% | -0.963% | 3.932% | 15.941% | -2.570% | 112.154% | 87.650% |
| Ligand Pharmaceuticals | 1.570% | 8.523% | 4.372% | 107.609% | 15.060% | 191.603% | 56.814% |
| United Therapeutics | 0.710% | -1.825% | 4.303% | 93.978% | 14.580% | 135.159% | 188.000% |
| Ionis Pharmaceuticals Inc. | 0.740% | 1.307% | 4.427% | 158.641% | -4.208% | 93.462% | 90.073% |
Comments
Exelixis (NASDAQ:EXEL) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $52.00 price target on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at HC Wainwright from $49.00 to $52.00. They now have a "buy" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
News
Exelixis: A Strong Contender in the Cancer Drug Market
Explore the exciting world of Exelixis (NASDAQ: EXEL) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade
Exelixis (NASDAQ: EXEL) is a relatively small biotech company with big dreams -- to become, as its executives said at a presentation in December, a "top five solid tumor oncology company."
The
Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026
While not the most popular biotech company on the market, Exelixis (NASDAQ: EXEL) has been quietly making a name for itself over the past five years, while delivering strong financial results and